The UK-based development and contract manufacturing organisation (CDMO) will take on the filling, packaging and testing of three Alliance injectable products.
They include Edrophonium for the diagnosis of auto immune disease myasthenia gravis, antituberculosis compound Isoniazid, and Pentagastrin, used to test medullary carcinoma of the thyroid.
Alliance says it was SCM’s capabilities to support speciality pharmaceutical firms with the supply of niche, and often low yield products that won them the contract.
David Yau, production, technical & quality director at Alliance, said: “We were impressed by SCM Pharma’s track record and are confident in their ability to deliver these three products.”
SCM now hopes the new deal will help them to gain a stronger footing in the world of CMDO, according to the head of communications Raman Sehgal.
He told Outsourcing-Pharma: “For the business it’s another commercial contract we’ve got under our belt.
“From a financial stand point, this is very good for sustainability in terms of having a constant stream of work from a large-scale pharmaceutical company.
“There’s also the possibility that Alliance will want us to look at manufacturing more of their products at a later stage.
“Finally, it’s good for generating business for us in the sense that it let’s the rest of the industry know that this is who we are and that we can handle novel, difficult and even dangerous products.
Graham Dotchin, commercial director at SCM Pharma, added: “We are delighted to be working with the team at Alliance Pharma and supporting them in the supply of these three sterile products.
“We hope this is the start of a long term relationship with Alliance Pharma and look forward to meeting their product supply requirements.”